Novavax, Inc. (NVAX:NASDAQ) closed at $11.01 on October 21, 2026, down 3.67% on the day. The stock trades 17.8% below its 52-week high of $13.39 and 77.6% above its 52-week low of $6.20. Over the past year, it gained 30.1%. Novavax, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 21, 2025, NVAX closed higher on 118 days (47%). Its best day was January 21, 2026 (+20.73%) and its worst was October 16, 2026 (-12.17%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 1 time.
Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Find more stocks like NVAX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.